A study investigating the effects of an adapted Qigong exercise programme in patients suffering from chronic low back pain

A randomised control trial comparing the effects of acupuncture combined with an add on Qigong programme, to acupuncture as a stand alone treatment and acupuncture combined with stretching exercises, in terms of pain, proprioception, functionality and psychosocial comorbidities.

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN15963005

Enrollment

Registered

2024-07-02

Start date

2023-03-03

Completion date

Unknown

Last updated

2024-07-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic low back pain Musculoskeletal Diseases

Interventions

Participants will be randomly allocated into three treatment Groups. All treatment groups will receive two treatments in the first four weeks and one treatment in the following four weeks. Group A (A

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Aged between 18-65 years old 2. Ability to provide consent, good knowledge of Greek 3. Low back pain lasting more than three months 4. Diagnosis of nonspecific chronic low back pain 5. Pain sensation on the VAS scale >5

Exclusion criteria

Exclusion criteria: 1. Participation in an exercise program in the previous three months 2. Participation in a physiotherapy program in the previous three months 3. Pain due to malignancy 4. Spondyloarthritis 5. Rheumatoid arthritis 6. Pregnancy 7. Postpartum (Up to six months from birth) 8. Knee osteoarthritis 9. Cognitive disability 10. Red Flags (e.g. suspicion of fracture, malignancy, cauda equina syndrome, rapid decrease in muscle strength, etc.)

Design outcomes

Primary

Measure	Time frame
Pain measured through the sensitivity to pressure stimuli using a digital algometer calculating pressure pain thresholds at baseline, and 8 and 22 weeks	—

Secondary

Measure	Time frame
The following Secondary outcome measures are assessed at baseline, 8 weeks and 22 weeks, unless stated: 1. Functional impairment measured using the five-repetition sit-to-stand test 2. Pain in conjunction with its psychosocial properties measured using the Short Form McGill Pain Questionnaire 3. Patients subjective measurement of their condition measured using the Global Perceived Effect scale at 8 weeks and 22 weeks 4. Disability measured using the Roland Morris Disability Questionnaire 5. Kinesiophobia measured using the Fear-Avoidance Beliefs Questionnaire (FABQ) 6. Depression and anxiety measured using the Hospital Anxiety and Depression Scale (HADS) 7. Catastrophising measured using the Pain Catastrophising Scale (PCS) 8. Quality of life measured using the 12-item Short Form Survey (SF-12) questionnaire 9. Compliance measured using a log that the participants complete at 8 weeks and 22 weeks 10. Medications measured using data recorded in a log	—

Measure

Time frame

The following Secondary outcome measures are assessed at baseline, 8 weeks and 22 weeks, unless stated: 1. Functional impairment measured using the five-repetition sit-to-stand test 2. Pain in conjunction with its psychosocial properties measured using the Short Form McGill Pain Questionnaire 3. Patients subjective measurement of their condition measured using the Global Perceived Effect scale at 8 weeks and 22 weeks 4. Disability measured using the Roland Morris Disability Questionnaire 5. Kinesiophobia measured using the Fear-Avoidance Beliefs Questionnaire (FABQ) 6. Depression and anxiety measured using the Hospital Anxiety and Depression Scale (HADS) 7. Catastrophising measured using the Pain Catastrophising Scale (PCS) 8. Quality of life measured using the 12-item Short Form Survey (SF-12) questionnaire 9. Compliance measured using a log that the participants complete at 8 weeks and 22 weeks 10. Medications measured using data recorded in a log

—

Countries

Greece

Contacts

Public ContactSpyridon;Spyridon Sotiropoulos;Sotiropoulos

;

ssotiropoulos@uniwa.gr;spiros_sotiropoylos@hotmail.com+306944331852;+306944331852

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026